Pfizer Inc.
PDE4 inhibitor (R)-4-(5-(4-methoxy-3-propoxyphenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol

Last updated:

Abstract:

The present invention relates to PDE4 inhibitor (R)-4-(5-(4-methoxy-3-propoxyphenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol including the crystalline monohydrate thereof.

Status:
Grant
Type:

Utility

Filling date:

4 Oct 2019

Issue date:

16 Mar 2021